


RECEIVED

Sheet 1 of 4

	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 21416/90042	SERIAL NO. 09/533,466
	INFORMATION DISCLOSURE STATEMENT		APPLICANT: Collart et al.	
			FILING DATE March 23, 2000	GROUP 1631

## U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						


## FOREIGN PATENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes No
	AL						
	AM						
	AN						
	AO						
	AP						
	AQ						

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

NO.	AR	ALLISON A. AND EUGUI E. (1996) "Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF)," <i>Clin Transplantation</i> 10: 77-84.
NO.	AS	ANTONINO L. et al. (1994) "Probing the active site of human IMP dehydrogenase using halogenated purine riboside 5'-monophosphates and covalent modification reagents," <i>Biochemistry</i> 33: 1760-1765.
NO.	AT	ANTONINO L. AND WU J. (1994) "Human IMP Dehydrogenase catalyzes the dehalogenation of 2 fluoro- and 2-chloro inosine 5'-monophosphate in the absence of NAD," <i>Biochemistry</i> 33: 1753-1759.
NO.	AU	ASHBAUGH C. AND WESSELS M. (1995) "Cloning, sequence analysis and expression of the group A streptococcal guaB gene encoding inosine monophosphate dehydrogenase," <i>Gene</i> 165: 57-60.
NO.	AV	BATEMAN A. (1997) "The structure of a domain common to archaeobacteria and the homocystinuria disease protein," <i>Protein Sequence Motif</i> 12-13. <i>TIBS</i> 22, 12-13
NO.	AW	BRUNGER A. et al. (1998) "Crystallography & NMR system: a new software suite for macromolecular structure determination," <i>Acta Crystal</i> 54: 905-921.
NO.	AX	COLLART F. AND HUBERMAN E. (1990) "Expression of IMP dehydrogenase in differentiating HL-60 cells," <i>Blood</i> 75: 570-576.
NO.	AY	COLLART F. et al. (1996) "Cloning, characterization and sequence comparison of the gene coding for IMP dehydrogenase from <i>pyrococcus furiosus</i> ," <i>Gene</i> 174: 209-216.
NO.	AZ	COLLART F. et al. (1996) "Cloning and characterization of the gene encoding IMP dehydrogenase from <i>Arabidopsis thaliana</i> ," <i>Gene</i> 174: 217-220.

Examiner



Date Considered

10/11/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BASED ON FORM PTO 1449

Please type a plus sign (+) inside this box → ☐



PTO/SB/08B (10-98)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB-control number.

<p>Substitute for form 1449B/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>		<i>Complete if Known</i>	
		Application Number	09/533,466
		Filing Date	March 23, 2000
		First Named Inventor	Frank R. Collart
		Group Art Unit	1631
		Examiner Name	Ogihara, N
Sheet 2	of 4	Attorney Docket Num	21416/90042

**OTHER REFERENCES -- NON PATENT LITERATURE DOCUMENTS**

Examiner initials*		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	BA	COLLART F. <i>et al.</i> (1996) "Cloning and characterization of the gene encoding IMP dehydrogenase from <i>Arabidopsis thaliana</i> ," <i>Gene</i> 174:217-220. <i>Duplicate</i>
MD	BB	HAGER P. <i>et al.</i> (1994) "Recombinant human inosine monophosphate dehydrogenase type I and type II proteins," <i>Biochemical Pharmacology</i> 49:1323-1329.
MD	BC	HALLORAN PF. (1996) "Molecular mechanisms of new immunosuppressants," <i>Clin Transplantation</i> 10:118-123.
MD	BD	HENDRICKSON W. (1991) "Determination of macromolecular structures from anomalous diffraction of synchrotron radiation," <i>Science</i> 254:51-58.
	BE	HOLBROOK <i>et al.</i> Lactate dehydrogenase. In <i>The Enzymes</i> , 3rd edition, pp. 191-292.
MD	BF	HUETE-PEREZ J. (1995) "Identification of the IMP binding site in the IMP dehydrogenase from <i>Tritichomonas foetus</i> ," <i>Biochemistry</i> 34:13889-13894.
MD	BG	JAYARAM H. (1992) "Clinical pharmacokinetic study of tiazofurin administered as a 1-hr infusion," <i>Int J. Cancer</i> 51:182-188.
MD	BH	KABSCH W AND SANDER C. (1983) "Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features," <i>Biopolymers</i> 22:2577-2637.
MD	BI	KERR K. AND HEDSTROM L. (1997) "The roles of conserved carboxylate residues in IMP dehydrogenase and identification of a transition state analog," <i>Biochemistry</i> 36:13365-13373.

Examiner Signature *[Signature]*

Date Considered 10/11/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)

Approved for use through 10/31/99, OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB-control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Complete if Known	
		Application Number	09/533,466
		Filing Date	March 23, 2000
		First Named Inventor	Frank R. Collart
		Group Art Unit	1631
		Examiner Name	Ogihara, N
Sheet 3	of 4	Attorney Docket Num	21416/90042

**OTHER REFERENCES – NON PATENT LITERATURE DOCUMENTS**

Examiner initials*		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
MD	CA	KIGUCHI <i>et al.</i> (1990) "Induction of cell differentiation in melanoma cells by inhibitors of IMP dehydrogenase: altered patterns of IMP dehydrogenase expression and activity," <i>Cell Growth and Differentiation</i> 1:259-270.
MD	CB	LINK J. AND STRAUB K. (1996) "Trapping of an IMP dehydrogenase-substrate covalent intermediate by mycophenolic acid," <i>J. Am. Chem. Soc.</i> 118: 2091-2092.
MD	CC	NAVAZA J. AND SALUDJIAN P. (1997) "AMoRe: an automated molecular replacement program package," <i>Methods in Enzymology</i> 275:581-594.
MD	CD	NIMMESGERN <i>et al.</i> (1996) "Conformational changes and stabilization of inosine 5'-monophosphate dehydrogenase associated with ligand binding and inhibition by mycophenolic acid," <i>Journal of Biological Chemistry</i> 271: 19421-19427.
MD	CE	OTWINOWSKI Z. AND MINOR W. (1997) "Processing of x-ray diffraction data collected in oscillation mode," <i>Methods in Enzymology</i> 276: 307-325.
MD	CF	PANNU <i>et al.</i> (1998) "Incorporation of prior phase information strengthens maximum-likelihood structure refinement," <i>Acta Crystl</i> 54: 1285-1294.
MD	CG	RAMAKRISHNAN V. AND BIOU V. (1997) "Treatment of multiwavelength anomalous diffraction data as a special case of multiple isomorphous replacement," <i>Methods in Enzymology</i> 276: 538-557.
MD	CH	RICE L. AND BRUNGER A. (1994) "Torsion angle dynamics: reduced variable conformational sampling enhances crystallographic structure refinement," <i>PROTEINS: Structure, Function, and Genetics</i> 19: 277-290.
MD	CI	SINTCHAK <i>et al.</i> (1996) "Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid," <i>Cell</i> 85: 921-390.

Examiner Signature

Date Considered 10/11/88

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐



PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB-control number.

<p>Substitute for form 1449B/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>		Complete if Known	
		Application Number	09/533,466
		Filing Date	March 23, 2000
		First Named Inventor	Frank R. Collart
		Group Art Unit	1631
		Examiner Name	Ogihara, N
Sheet 4	of 4	Attorney Docket Num 21416/90042	

**OTHER REFERENCES – NON PATENT LITERATURE DOCUMENTS**

Examiner initials*		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
MD	DA	SMITH <i>et al.</i> (1991) "A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection," <i>The New England Journal of Medicine</i> 325: 24-29.
MD	DB	WANG <i>et al.</i> (1996) "Inactivation of inosine 5'-monophosphate dehydrogenase by the antiviral agent 5-ethynyl-1-beta-D-Ribofuranosylimidazole-4-Carboxamide 5'-monophosphate," <i>Biochemistry</i> 35:95-101.
MD	DC	WESTBROOK E. AND NADAY I. (1997) "Charge-coupled device-based area detectors," <i>Methods in Enzymology</i> 276: 244-268.
MD	DD	WHITBY F. (1997) "Crystal structure of tritrichomonas foetus inosine-5' monophosphate dehydrogenase and the enzyme-product complex," <i>Biochemistry</i> 36:10666-10674.
MD	DE	XIANG B. AND MARKHAM G. (1997) "Probing the mechanism of inosine monophosphate dehydrogenase with kinetic isotope effects and NMR determination of hydride transfer stereospecificity," <i>Archives of Biochemistry and Biophysics</i> 348: 378-382.
MD	DF	ZHOU <i>et al.</i> (1997) "Expression, purification, and characterization of inosine 5'-monophosphate dehydrogenase from borrelia burgdorferi," <i>Journal of Biological Chemistry</i> 272:21977-21981.
	DG	
	DH	

Examiner Signature [Signature]

Date Considered 10/11/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

†Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.